Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
Centogene N.V. (symbol: CNTG) is a leading global company in the field of genetic diagnostic testing for rare hereditary diseases. With an expansive test portfolio covering over 2,800 genes, as well as biochemical and biomarker tests, the company offers unparalleled expertise in whole exome sequencing and whole genome sequencing. Centogene's mission is to provide data-driven, life-changing answers to patients, physicians, and pharmaceutical companies by diagnosing the root causes of symptoms early on.
Centogene leverages its unique CentoMD® mutation database, integrating genetic and clinical information to deliver the highest quality genetic testing and biomarker development. This extensive database allows the company to maintain the largest systematic documentation of genetic results worldwide.
Beyond individual diagnostic services, Centogene is a pivotal partner for pharmaceutical companies, offering essential services such as early patient recruitment, epidemiological insights, biomarker discovery, and patient monitoring. The company operates in two main segments: pharmaceutical and diagnostics, serving regions including Europe, the Middle East, North America, and Latin America.
Recent achievements include the launch of innovative genomic and multiomic products, a significant joint venture in Saudi Arabia, and expanded collaborations with long-standing and new pharma partners. Despite the challenges posed by current financial markets, Centogene remains committed to growth and profitability, exploring strategic alternatives to unlock value for its stakeholders.
With ISO, CAP, and CLIA certified multiomic reference laboratories in Germany, Centogene's research and development efforts have led to over 285 peer-reviewed publications. The company's pioneering work in rare and neurodegenerative diseases has fostered collaborations with over 50 pharmaceutical partners, accelerating drug discovery and development.
To discover more about Centogene's products, pipeline, and patient-driven purpose, visit their website and follow them on LinkedIn.
Centogene N.V. (Nasdaq: CNTG) has appointed Miguel Coego Rios as Managing Director and permanent Chief Financial Officer, effective June 22, 2022. Coego Rios, who was previously the Interim CFO and joined Centogene in February 2022 as EVP Finance & Legal, has extensive experience in the biopharma sector. His focus will be on optimizing operations, enhancing shareholder value, and ensuring financial health. Centogene continues its mission in the rare disease space, leveraging a global data platform for diagnostics and drug development.
Centogene has expanded its collaboration with Agios Pharmaceuticals to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies, focusing on the treatment of pyruvate kinase (PK) deficiency in children under 18. PYRUKYND® (mitapivat), already FDA-approved for adults, represents the first disease-modifying treatment for this rare disorder. Centogene will provide genetic testing and centralized lab support for trials aimed at assessing the drug's efficacy in pediatric patients. This partnership enhances Centogene's role in advancing critical treatments for under-served patient communities.
Centogene has announced that its CentoCloud platform is now CE-marked under the In Vitro Diagnostics Directive (98/79/EC), enabling its commercialization in the European Economic Area (EEA). This cloud-based SaaS solution supports genetic disease diagnostics, using a validated bioinformatics pipeline for Next Generation Sequencing (NGS) data analysis. The CE-marking signifies CentoCloud as one of the few CE-marked IVD software for genomic diagnostics available via the cloud, emphasizing Centogene's dedication to high industry standards and patient access to genetic testing.
Centogene N.V. (Nasdaq: CNTG) has collaborated with various genetic organizations to publish updated Whole Genome Sequencing (WGS) recommendations in the European Journal of Human Genetics. The guidelines aim to standardize clinical applications of WGS tests, facilitating quicker diagnoses and improving health outcomes for rare diseases. With testing conducted on over 650,000 individuals, WGS has gained popularity, contributing to double-digit growth in the number of tests conducted in FY2021. The initiative underscores Centogene's commitment to advancing genetic diagnostics.
Centogene N.V. (Nasdaq: CNTG) has announced its participation in the virtual H.C. Wainwright Global Investment Conference from May 23–26, 2022. The company's management, including CEO Kim Stratton and CFO Miguel Coego, will present and hold one-on-one meetings with investors. A recording of the presentation will be available from May 24, 2022, on Centogene's investor relations website. Centogene focuses on diagnosing and researching rare diseases, utilizing a unique platform with data from over 650,000 individuals across 120 countries.
Centogene extends its partnership with Takeda to provide genetic testing for rare metabolic and neurodegenerative diseases, emphasizing timely diagnosis as key to patient care.
The renewed contract aims to enhance access to diagnostics for lysosomal storage disorders like Fabry and Gaucher diseases. With over 29,000 healthcare professionals in its network and the CENTOGENE Biodatabank, the collaboration seeks to improve treatment outcomes for underserved patient communities globally. This partnership builds on a previous agreement initially made in 2015.
Centogene N.V. (CNTG) reported a 48% revenue growth in FY 2021, totaling €189.9 million, and an 11% increase in its Core Business revenues, reaching €43.5 million. Despite a 39% decrease in Q4 revenues to €42.9 million, driven by a drop in COVID-19 testing, the company noted growth in Pharma and Diagnostics segments. A net loss of €46.9 million was recorded for FY 2021, up from €21.4 million in FY 2020. The company closed a $62 million financing round and anticipates 2022 revenue guidance between €68 million to €70 million, focusing on pharma and diagnostics.
Centogene N.V. (Nasdaq: CNTG) announced that CEO Kim Stratton will address attendees at the BIO-Europe Spring conference on March 31, 2022. This event, running from March 28-31, is Europe’s largest digital partnering event for biopharma professionals, featuring networking opportunities from over 50 countries. Stratton's session will focus on CENTOGENE’s role as a partner in rare and neurodegenerative diseases, highlighting their global Bio/Databank and extensive physician network. The company aims to support biopharma partners in treatment development and market access strategies.
Centogene N.V. (Nasdaq: CNTG) will release its financial results for Q4 and full-year 2021 on March 30, 2022, at 2 p.m. CEST / 8 a.m. EDT. A conference call and webcast will follow to discuss these results. The company specializes in diagnosing and treating rare diseases, leveraging a platform built on a global data repository of over 600,000 patients. Centogene collaborates with over 30 pharmaceutical partners, aiming to accelerate orphan drug development through enhanced patient identification and treatment strategies.
Centogene N.V. (Nasdaq: CNTG) has expanded its data access and collaboration agreement with Pfizer to include a new research project aimed at uncovering rare genetic causes of neurodegenerative diseases. This follows an initial agreement established in November 2019, which granted Pfizer access to Centogene’s Bio/Databank for drug discovery. The collaborative research will enhance the validation of genetic targets using existing patient samples, positioning Centogene uniquely in data-driven drug discovery for rare diseases.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
What does Centogene N.V. specialize in?
What is CentoMD®?
Which segments does Centogene operate in?
What regions does Centogene serve?
Who are Centogene’s main partners?
What are some recent achievements of Centogene?
How does Centogene contribute to drug discovery?
What research certifications does Centogene hold?
How extensive is Centogene's physician network?
Where can I learn more about Centogene?
